HGF / CAT double-gene nano-drug as well as preparation method and application thereof
By using membrane-fusion liposome-nuclear-targeted polymer hybrid nanocarrier with pHGF and pCAT in lower limb ischemic diseases, the problem of inefficient monogene therapy is solved and angiogenesis is significantly improved and blood perfusion improve the treatment effect of the disease.
Patent Information
- Application Number
- CN202411105643.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
AI Technical Summary
The existing monogene therapy technology is inefficient in lower limb ischemic diseases and is difficult to effectively promote angiogenesis, resulting in poor treatment effect and high disability and mortality rates.
Using a dual-gene nanodrug based on membrane fusion liposome-nuclear targeting polymer hybrid nanocarrier, including hepatocyte growth factor plasmid (pHGF) and catalase plasmid (pCAT), targeting the nucleus through antibodies to improve the Gene transfection efficiency and drug delivery effect.
It significantly improves the efficiency of gene therapy, promotes angiogenesis and lower limb blood flow perfusion, improves the clinical treatment effect of ischemic diseases, and reduces the disability and mortality rate.
Smart Images

Figure CN118987271A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of drug preparation, and in particular to HGF / CAT dual-gene nanomedicine and its preparation method and application. Background Art
[0002] Ischemic disease of the lower limb refers to partial or complete occlusion of blood vessels around the limb, leading to symptoms such as pain, ulcers, and gangrene. This disease has high morbidity, disability, and mortality, affecting approximately 10% of the global population. Despite advances in surgical and endovascular treatments, meeting the clinical needs of patients remains challenging. There is an urgent need to further improve the treatment of ischemic limb injuries, reduce disability and mortality, and improve the quality of life of patients.
[0003] The main problem of lower limb ischemia is the reduced blood perfusion of leg muscles and soft tissues. Therapeutic angiogenesis provides a new approach for the treatment of lower limb ischemia, especially by promoting the development of ischemic collateral circulation through gene therapy, such as hepatocyte growth factor plasmid (pHGF) therapy, which can effectively alleviate lower limb ischemia. However, due to the limitations of single gene therapy and the low efficiency of gene transfection, the application of such technology in the treatment of lower limb ischemia is still in the clinical research stage. Further research is needed to enhance the understanding of gene therapy to promote angiogenesis.
[0004] Therefore, this study developed a dual-gene nanodrug based on membrane fusion liposome-core-targeted polymer hybrid nanocarrier, encapsulating pHGF and pCAT, for the treatment of lower limb ischemic diseases. Summary of the invention
[0005] The present application provides a method for preparing an HGF / CAT dual-gene nanomedicine to solve the above-mentioned problems.
[0006] The technical solution adopted by the present invention is as follows:
[0007] A method for preparing HGF / CAT dual gene nanomedicine comprises the following steps:
[0008] (1) adding hepatocyte growth factor plasmid and catalase plasmid into a solvent, and then adding PVA solution to prepare HGF / CAT-NPs suspension;
[0009] (2) mixing the HGF / CAT-NPs suspension and the Anti-LMNB1 antibody to prepare the HGF / CAT-NPs+B suspension;
[0010] (3) adding the HGF / CAT-NPs+B suspension into the lipid film to prepare the HGF / CAT-LNPs suspension;
[0011] (4) Mixing the HGF / CAT-LNPs suspension and HVJ-E to obtain a finished product.
[0012] Furthermore, in step (1), the mass ratio of the hepatocyte growth factor plasmid to the catalase plasmid is 1:0.8-1.2.
[0013] Furthermore, in step (1), the solvent includes protamine sulfate, poly(lactic acid-co-glycolic acid), dichloromethane and water.
[0014] Further, 2.5-3.5 mg of protamine sulfate was added to water to prepare a protamine sulfate aqueous solution, and the protamine sulfate aqueous solution was added to dichloromethane containing 70-90 mg of polylactic acid-co-glycolic acid copolymer, and stirred at 20000 rpm / min in an ice bath for 4-6 minutes to prepare a solvent.
[0015] Further, distilled water containing hepatocyte growth factor and peroxidase was slowly added to the solvent while stirring, and then added to 15 ml of 1% PVA (polyvinyl alcohol) solution and mixed. The resulting mixture was stirred and evaporated for 3 hours to remove dichloromethane, thereby obtaining HGF / CAT-NPs.
[0016] Furthermore, in step (2), the ratio of the Anti-LMNB1 antibody to hepatocyte growth promoting factor is 9-11 μL: 0.9-1.1 mg.
[0017] Furthermore, in step (2), the HGF / CAT-NPs suspension and Anti-LMNB1 antibody are shaken at 90-110 rpm / min for 4-6 min.
[0018] Furthermore, in step (3), the lipid membrane is prepared by using egg yolk phosphatidylcholine, dioleoyl-trimethylammonium chloride, cholesterol and dichloromethane.
[0019] Further, dichloromethane containing 2 mg of egg yolk phosphatidylcholine, 2 mg of dioleoyl-trimethylammonium chloride and 1 mg of cholesterol was evaporated at 65° C. to form a lipid film.
[0020] Furthermore, in step (4), the ratio of HVJ-E to hepatocyte growth factor is 45-55 μL: 0.9-1.1 mg.
[0021] Furthermore, in step (4), the HGF / CAT-LNPs suspension and HVJ-E are mixed by centrifugation at 13000-17000 rpm / min.
[0022] Furthermore, the HGF / CAT dual-gene nanomedicine is used in the preparation of drugs for lower limb ischemic diseases.
[0023] The beneficial effects of the embodiments of the present application compared with the prior art are:
[0024] The present invention encapsulates hepatocyte growth factor plasmid (pHGF) and catalase plasmid (pCAT) to prepare dual-gene nanoparticles (HGF / CAT-FLNPs). Polylactic acid-glycolic acid is added during the preparation process, and anti-lamin B1 antibody and polylactic acid-glycolic acid are combined to target the cell nucleus through antigen-antibody reaction, thereby achieving efficient delivery of the internalized gene to the cell nucleus.
[0025] In the present application, egg yolk lecithin, dioleoyl-trimethylammonium chloride, cholesterol and dichloromethane are used to prepare liposomes, and the liposomes are added to the preparation of HGF / CAT dual-gene nanomedicine, which can solve the problem of low gene transfection due to the negative charge on the surface of polylactic acid-glycolic acid and the low lysosomal escape efficiency, and further improve the delivery efficiency of HGF / CAT dual-gene nanomedicine.
[0026] Adding adsorbed Sendai virus envelope protein (HVJ-E) during the preparation of HGF / CAT dual-gene nanomedicine can improve the fusion effect of each component and enhance the therapeutic effect of the drug on lower limb ischemic diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Particle size distribution of HGF / CAT-FLNPs prepared in Example 1
[0028] Figure 2 Potential distribution diagram of HGF / CAT-FLNPs prepared in Example 1
[0029] Figure 3 Particle size stability of HGF / CAT-FLNPs prepared in Example 1
[0030] Figure 4 Potential stability of HGF / CAT-FLNPs prepared in Example 1
[0031] Figure 5 Example 1 Cytocompatibility of HGF / CAT-FLNPs
[0032] Figure 6 Example 1: Effect of HGF / CAT-FLNPs on cell proliferation in H2O2 environment
[0033] Figure 7 The HGF / CAT-FLNPs prepared in Example 1 inhibited ischemic lower limb gangrene in mice, wherein the left side shows the lower limb of the mouse before treatment, and the right side shows the lower limb of the mouse after treatment with HGF / CAT-FLNPs.
[0034] Figure 8 Example 1 HGF / CAT-FLNPs were prepared to promote the recovery of motor function of ischemic lower limbs in mice, wherein the left side is the control group and the right side is the experimental group.
[0035] Fig. 9 The HGF / CAT-FLNPs prepared in Example 1 promoted the recovery of blood perfusion in ischemic lower limbs of mice, wherein the left side is the control group and the right side is the experimental group. DETAILED DESCRIPTION
[0036] It should be understood that the present invention is not limited to the specific compositions, methods or schemes described herein. In addition, unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. It should also be understood that the terms used herein are only used for the purpose of describing specific embodiments and are not intended to limit the scope of the present invention, which is limited only by the claims. The experimental methods used in the examples are conventional methods unless otherwise specified; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial sources.
[0037] pHGF: Hepatocyte Growth Factor Plasmid (Source: Wuhan Miaoling Technology Co., Ltd.)
[0038] pCAT: Catalase plasmid (Source: Wuhan Miaoling Technology Co., Ltd.)
[0039] Anti-LMNB1 antibody: Anti-lamin B1 antibody (Source: Wuhan Boster Biotechnology Co., Ltd.)
[0040] H2O2: hydrogen peroxide; CAT: catalase
[0041] PLGA: poly(lactic-co-glycolic acid); PVA: poly(vinyl alcohol)
[0042] HVJ-E: Sendai virus envelope protein
[0043] DOTAP: Dioleoyl-trimethylammonium chloride
[0044] Example 1
[0045] Distilled water containing 3 mg of protamine sulfate was slowly added to 80 mg of PLGA in dichloromethane, with a dichloromethane dosage of 2 mL, and stirred at high speed (20,000 rpm / min) in an ice bath for 5 minutes. Subsequently, distilled water containing 1 mg of pHGF and 1 mg of pCAT was slowly added to the above solution while stirring, and then added to 15 ml of 1% PVA solution. The resulting mixture was stirred and evaporated for 3 hours to remove dichloromethane to obtain HGF / CAT-NPs.
[0046] 10 μL Anti-LMNB1 antibody was added to the HGF / CAT-NPs suspension and shaken at 100 rpm / min for 10 min. Dichloromethane containing 2 mg egg yolk phosphatidylcholine, 2 mg DOTAP (dioleoyl-trimethylammonium chloride) and 1 mg cholesterol was evaporated at 65 °C to form a lipid film. Then HGF / CAT-NPs+B was dropped and stirred above the lipid film to obtain HGF / CAT-LNPs. Finally, 50 μL HVJ-E was added to the HGF / CAT-LNPs and centrifuged at 15000 rpm / min for 3 min to obtain HGF / CAT-FLNPs.
[0047] Experimental Example 1 Characterization of HGF / CAT-FLNPs
[0048] Detection of particle size, potential and stability: A ZS zeta particle size analyzer was used to measure the particle size and zeta potential of the HGF / CAT-FLNPs prepared in Example 1. The particle size was measured every 5 days (n=3) over a period of 30 days to evaluate the stability of the HGF / CAT-FLNPs.
[0049] See also Figures 1 to 4 In Example 1, lipid polymer was used as a carrier material, and nanoparticles HGF / CAT-FLNPs that can be used for gene delivery were prepared by high-speed stirring and solvent evaporation. Within 15 days, the particle size distribution and potential distribution of HGF / CAT-FLNPs were characterized and detected by a particle size potentiometer. The results showed that the prepared HGF / CAT-FLNPs had a small fluctuation in the change range and showed good stability.
[0050] Test Example 2 Cell Compatibility
[0051] Experimental process: C2C12 cells were seeded in 96-well plates at a density of 5×10 4 cells / well and incubated for 24 hours. HGF or HGF / CAT-FLNPs (each containing 10μg HGF) were added to the cells and incubated for 48 hours. The control group was treated with the same volume of serum-free medium (or medium containing 10μM H2O2) for 48 hours. After incubation, 5mg / mL MTT solution was added and incubated for 4 hours. The supernatant was then discarded, 150μL DMSO was added, and shaken for 5 minutes. The cell compatibility of HGF / CAT-FLNPs was evaluated using a multifunctional enzyme marker. Cell viability was calculated using the following formula:
[0052] Cell viability (%) = (OD value of experimental group / OD value of control group) × 100%
[0053] See also Figure 5 to Figure 6The cell compatibility of HGF / CAT-FLNPs was detected by MTT method. FLNPs were loaded with therapeutic genes pHGF and pCAT to prepare HGF / CAT-FLNPs. After HGF / CAT-FLNPs were co-incubated with C2C12, the cell proliferation was observed. The experimental results showed that HGF / CAT-FLNPs did not affect the proliferation of C2C12 under normal conditions, but promoted the proliferation of C2C12 in the environment of H2O2 (2.5μM), indicating that HGF / CAT-FLNPs significantly enhanced the resistance of cells to H2O2-induced damage.
[0054] Test Example 3 Animal Test
[0055] Experimental procedure: Six-week-old male ICR mice were randomly divided into PBS group and HGF / CAT-FLNPs group. The mouse hind limb ischemia model was established. HGF / CAT-FLNPs (0.67 mg / mL, 80 μL) were intramuscularly injected into the gastrocnemius muscle of the ischemic hind limb on days 1, 3, and 5, for a total of 3 injections.
[0056] The blood perfusion of the hind limbs was monitored by laser Doppler line scanner on days 1, 4, 7, 14, 21, and 28 after surgery, and the results were analyzed using moorLDI Review V6.2 software. The morphology of the limbs was visually observed after surgery, and the ischemic gangrene of the hind limbs was recorded by photography.
[0057] To measure the footprints, cut the A4 paper and put it in a cardboard box. Prepare red and blue inks. Evenly dye the front feet of each mouse with red ink and the back feet with blue ink. Then put the mouse at one end of the A4 paper in the cardboard box. After the mouse walks to the other end of the A4 paper, remove the paper with footprints to evaluate the recovery of the mouse's motor function.
[0058] See also Figures 7 to 9 , ischemic hind limb gangrene was observed in mice, indicating successful modeling. After treatment with HGF / CAT-FLNPs, ischemic lower limb gangrene in mice was inhibited, and ischemic hind limb gangrene was significantly improved. Subsequently, the recovery of motor function after treatment was evaluated. The mice in the PBS group showed a certain degree of lameness and toe curling during walking, while no lameness was observed in the HGF / CAT-FLNPs group ( Figure 8 After the treatment, each group was tested for blood perfusion recovery. Compared with the PBS group, the blood perfusion recovery in the HGF / CAT-FLNPs group was significantly improved, indicating that HGF / CAT-FLNPs had a significant effect in promoting vascular microcirculation.
[0059] In the present application, catalase (CAT) can catalyze the decomposition of H2O2 into water and oxygen, and increasing the expression of CAT reduces the level of H2O2 in ischemic tissues. The combined delivery of pCAT and pHGF may help to improve pathological oxidative stress and enhance the stability of therapeutic angiogenesis. However, since naked genes are easily attacked by nucleases or oxidative stress and lose their original biological activity, and exhibit poor cell membrane permeability, polylactic acid-glycolic acid copolymers, Anti-LMNB1 antibodies, lipid membranes, etc. are added during the preparation of pCAT and pHGF in the present application, which can achieve efficient delivery of the internalized genes to the cell nucleus, promote vascular microcirculation, etc., and achieve the effect of treating lower limb ischemic diseases.
[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for preparing HGF / CAT dual gene nanomedicine, characterized in that: The following steps are involved: (1) adding a hepatocyte growth factor plasmid and a catalase plasmid into a solvent, and then adding a polyvinyl alcohol solution to prepare an HGF / CAT-NPs suspension; (2) mixing the HGF / CAT-NPs suspension and the Anti-LMNB1 antibody to prepare the HGF / CAT-NPs+B suspension; (3) adding the HGF / CAT-NPs+B suspension into the lipid film to prepare the HGF / CAT-LNPs suspension; (4) The HGF / CAT-LNPs suspension and HVJ-E are mixed and centrifuged to obtain a finished product.
2. The method for preparing the HGF / CAT dual gene nanomedicine according to claim 1, characterized in that: In step (1), the mass ratio of the hepatocyte growth factor plasmid to the catalase plasmid is 1:0.8-1.
2.
3. The method for preparing the HGF / CAT dual gene nano drug according to claim 1, characterized in that: In step (1), the solvent includes protamine sulfate, poly(lactic acid-co-glycolic acid), dichloromethane and water.
4. The method for preparing the HGF / CAT dual gene nanomedicine according to claim 1, characterized in that: In step (2), the ratio of the Anti-LMNB1 antibody to the hepatocyte growth factor plasmid is 9-11 μL: 0.9-1.1 mg.
5. The method for preparing the HGF / CAT dual gene nano drug according to claim 1, characterized in that: In step (2), the mixing is performed by oscillating at 90 to 110 rpm / min.
6. The method for preparing the HGF / CAT dual gene nanomedicine according to claim 1, characterized in that: In step (3), the lipid membrane is prepared by using egg yolk phosphatidylcholine, dioleoyl-trimethylammonium chloride, cholesterol and dichloromethane.
7. The method for preparing the HGF / CAT dual gene nanomedicine according to claim 1, characterized in that: In step (4), the ratio of HVJ-E to hepatocyte growth factor plasmid is 45-55 μL: 0.9-1.1 mg.
8. The method for preparing the HGF / CAT dual gene nanomedicine according to claim 1, characterized in that: In step (4), the centrifugal rotation speed is 13000-17000 rpm / min.
9. A HGF / CAT dual gene nanomedicine, characterized in that: The method is obtained by the preparation method according to any one of claims 1 to 8.
10. Use of the HGF / CAT dual gene nanomedicine as claimed in claim 9 in the preparation of drugs for lower limb ischemic diseases.
Citation Information
Cited By
Cell nucleus targeting nanoparticle, pharmaceutical composition, related preparation method and application
CN117323441A
